Pancreatic Cancer Clincial Trials - Dana-Farber Cancer Institute

New Patient? For appointments or second opinions: Adults: (877) 442-DFCI (442-3324) Children: (888) PEDI-ONC (733-4662) or complete the Appointment Request Form Online Specialty Consultations International Patients Referring Physician? To refer an adult patient: (877) 441-DFCI (441-3324) To refer a pediatric patient: (888) PEDI-ONC (733-4662) or complete the Patient Referral Form

Pediatric Treatment Centers and Clinical Services Care Team Patient And Family Support Care Quality and Patient Safety Patient Stories For Survivors of Childhood Cancer Browse by Cancer Type A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

New Patient? For appointments or second opinions: Adults: (877) 442-DFCI (442-3324) Children: (888) PEDI-ONC (733-4662) or complete the Appointment Request Form Your Child's Care Team For International Patients Referring Physician? To refer an adult patient: (877) 441-DFCI (441-3324) To refer a pediatric patient: (888) PEDI-ONC (733-4662) or complete the Patient Referral Form

Pancreatic Cancer Clinical Trials

Showing 1-4 of 4 items

Immunotherapy Study for Surgically Resected Pancreatic Cancer
The purpose of this study is to assess overall survival after treatment with a regimen of adjuvant therapy (Gemcitabine alone or with 5-FU chemoradiation) with or without HyperAcute®-Pancreas (algenpantucel-L) immunotherapy in subjects who have undergone surgical resection.
Diagnoses: Gastrointestinal Malignancies, Pancreatic Cancer
Status: Recruiting

Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery
This randomized phase III trial is studying gemcitabine hydrochloride and erlotinib hydrochloride to see how well they work compared with gemcitabine hydrochloride alone followed by the same chemotherapy regimen with or without radiation therapy and capecitabine or fluorouracil in treating patients with pancreatic cancer that was removed by surgery. Drugs used in chemotherapy, such as gemcitabine hydrochloride, capecitabine, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells. Giving chemotherapy together with or without erlotinib hydrochloride and/or radiation therapy after surgery may kill any tumor cells that remain after surgery. It is not yet known whether chemotherapy is more effective when given with or without erlotinib hydrochloride and/or radiation therapy in treating pancreatic cancer
Diagnoses: Radiation Oncology, Pancreatic Cancer
Status: Recruiting

M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
People with primary metastatic pancreatic cancer will be treated with nab-paclitaxel and gemcitabine in combination with an investigational agent called M402. It is made from heparin, which is a well known blood thinner. Blood thinners have been shown in prior animal and human studies to have anti-cancer effects. M402 has been re-engineered from heparin to have much lower blood thinning activity while keeping the anti-tumor activity. The investigators are testing whether M402 administered in combination with nab-paclitaxel and gemcitabine may be more effective than nab-paclitaxel and gemcitabine.
Diagnoses: Gastrointestinal Malignancies, Pancreatic Cancer
Status: Recruiting

Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients
This phase Ib study includes two phases: dose escalation phase and safety expansion phase. During the dose escalation phase, successive cohorts of eligible patients (minimum 3 and maximum 6 evaluable patients per cohort) will receive increasing oral doses of LDE225 administered on a continuous once daily (QD) dose in combination of gemcitabine. This phase of the study will determine the maximum tolerated dose (MTD) and/ or recommended dose for expansion (RDE) of LDE225 administered in combination with gemcitabine in locally advanced or metastatic pancreatic adenocarcinoma patients. During the safety expansion phase, once the MTD of LDE225 is established, additional patients will be enrolled and treated at the MTD of LDE225 in combination with gemcitabine in order to further evaluate its safety, tolerability and explore the potential efficacy of the combined treatments on the patients in locally advanced or metastatic pancreatic adenocarcinoma.
Diagnoses: Gastrointestinal Malignancies, Pancreatic Cancer
Status: Recruiting

Showing 1-4 of 4 items

Highlight Glossary Terms

Treatment Centers and Clinical Services Care Team Patient And Family Support Care Quality and Patient Safety Patient Stories For Adult Cancer Survivors Browse by Cancer Type A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials Research Advances Featured Research Departments and Centers Integrative Research Centers Core Facilities Research Administration Technology Transfer Find a Researcher